Related Experiment Videos
Infliximab and nephrotic syndrome
George Chin1, Grant Luxton, Jennet M Harvey
1Renal Unit, Sir Charles Gairdner Hospital, Nedlands. george.chin@phnt.swest.nhs.uk
Summary
Infliximab, a TNF-alpha inhibitor, is widely used for inflammatory conditions. This case report highlights a rare renal complication: infliximab-induced membranous nephropathy, emphasizing the need for awareness of uncommon side effects.
Area of Science:
- Immunology
- Nephrology
- Rheumatology
Background:
- Infliximab is a monoclonal antibody targeting tumor necrosis factor-alpha (TNF-alpha).
- It is a common treatment for rheumatoid arthritis, inflammatory bowel disease, psoriasis, and ankylosing spondylitis.
- While infection is a known side effect, renal complications are less recognized.
Observation:
- This report details a patient experiencing a probable case of drug-induced kidney disease.
- The patient developed membranous nephropathy.
- This condition is suspected to be linked to infliximab treatment.
Findings:
- A probable association between infliximab therapy and the development of membranous nephropathy was identified.
- This suggests a potential, albeit uncommon, renal adverse effect of infliximab.
- The mechanism underlying this renal complication requires further investigation.
Implications:
- Clinicians should consider renal complications, specifically membranous nephropathy, in patients treated with infliximab presenting with kidney issues.
- Increased vigilance for uncommon side effects of biologic therapies is warranted.
- Further research into the pathogenesis of infliximab-induced nephropathy may inform patient monitoring and management strategies.